Contact
Please use this form to send email to PR contact of this press release:
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis
TO:
Please use this form to send email to PR contact of this press release:
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis
TO: